Bioventus Inc. (BVS)
| Market Cap | 1.11B +152.4% |
| Revenue (ttm) | 585.64M +3.9% |
| Net Income | 57.30M +463.3% |
| EPS | 0.81 +426.7% |
| Shares Out | 84.09M |
| PE Ratio | 16.26 |
| Forward PE | 15.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 682,426 |
| Open | 13.52 |
| Previous Close | 13.33 |
| Day's Range | 13.07 - 13.73 |
| 52-Week Range | 6.47 - 15.89 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 17.60 (+33.84%) |
| Earnings Date | Nov 2, 2026 |
About BVS
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price target is $17.6, which is an increase of 33.84% from the latest price.
News
Bioventus Earnings Call Transcript: Q3 2026
Q3 revenue rose 3% and adjusted EBITDA margin expanded, with strong Pain Treatments and growth-driver momentum offset by BGS weakness. FY revenue guidance was reduced, while adjusted EPS guidance was reaffirmed and cash generation supported further debt repayment.
Bioventus Earnings release: Q3 2026
Bioventus released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Bioventus Quarterly report: Q3 2026
Bioventus has published its Q3 2026 quarterly earnings report on November 2, 2026.
Bioventus Slides: Q3 2026
Bioventus has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Bioventus reports Q3 EPS 17c, consensus 16c
Reports Q3 revenue $142.442M, consensus $149.52M. “Bioventus (BVS) delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA,” said Rob Claypoo...
Bioventus reaffirms FY26 adjusted EPS view 75c-79c, consensus 78c
For the twelve months ending December 31, 2026, the Company is: Presenting Adjusted Cash from Operations of $84M-$89M, which excludes the cash flow impact of the costs related to the…
Bioventus Reports Third Quarter Financial Results
DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the...
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Bioventus price target raised to $19 from $15 at Canaccord
Canaccord raised the firm’s price target on Bioventus (BVS) to $19 from $15 and keeps a Buy rating on the shares. The firm updated its mode following Q2 results and…
Bioventus price target raised to $18 from $16 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Bioventus (BVS) to $18 from $16 and keeps a Buy rating on the shares after mixed Q2 results and newly announced strategic alternatives…
Bioventus price target raised to $18 from $14 at Barrington
Barrington raised the firm’s price target on Bioventus (BVS) to $18 from $14 and keeps an Outperform rating on the shares. The firm views the company’s Q2 report as mixed.
Bioventus reports Q2 EPS 22c, consensus 22c
Reports Q2 revenue $153.21M, consensus $155.64M. “Bioventus (BVS) continued its positive momentum in the second quarter, with solid performance that positions us well for continued success in the seco...
Bioventus backs FY26 adjusted EPS view 75c-79c, consensus 78c
Backs FY26 revenue view $600M-$610M, consensus $605.76M.
Bioventus initiates review of strategic alternatives
The company said, “Following receipt of a recent unsolicited acquisition proposal and multiple other expressions of interest, Bioventus (BVS) today announced that it has initiated a review of strategi...
Bioventus Earnings Call Transcript: Q2 2026
Q2 saw 4% revenue growth, strong double-digit gains in Pain Treatments, and margin expansion, with adjusted EPS up 24% year-to-date. Strategic review is underway after acquisition interest, while full-year guidance and accelerated H2 growth are reaffirmed.
Bioventus Earnings release: Q2 2026
Bioventus released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Bioventus Quarterly report: Q2 2026
Bioventus has published its Q2 2026 quarterly earnings report on August 5, 2026.
Bioventus Slides: Q2 2026
Bioventus has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Bioventus Reports Second Quarter Financial Results
DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the...
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Bioventus management to meet with Barrington
Meeting to be held in Denver on June 24 hosted by Barrington.
Bioventus Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Revenue and margin growth continue, with 2026 guidance at $605 million and EBITDA margins above 20%. Focus is on debt reduction, investing in high-growth products like PNS and PRP, and expanding internationally. Portfolio and profitability improvements are supported by disciplined capital allocation and strong execution.
Bioventus Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and governance procedures. All director nominees were elected and the auditor appointment was ratified, with final vote results to be published in a Form 8-K. No shareholder questions were submitted.
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President an...